The tablet era is now a live comparison market.
Oral Wegovy went on sale through UK pharmacy services this month, NICE opened its review of Eli Lilly's rival pill, and fresh figures show how large the GLP-1 market has become.
The biggest shift in weight-loss treatment since injectable GLP-1s arrived is now playing out on the high street: oral Wegovy went on sale through Boots and a wave of online pharmacies this month, with prices already ranging from £79 introductory offers to £269 a month before discounts. Meanwhile NICE has begun weighing up whether Eli Lilly's rival pill, orforglipron, should get NHS backing, a decision that will not land until the autumn. Away from weight loss, at-home venous blood testing is scaling up nationally and the NHS is exploring the same territory for its own health checks. The direction of travel is clear: private weight-loss care is moving from injection to tablet, and diagnostics are moving from clinic to doorstep.
In this round-up
Oral Wegovy goes on sale in UK pharmacies, and a price war is already underway
The Wegovy tablet, a once-daily pill version of semaglutide, became available through Boots Online Doctor and a growing list of online pharmacies this month, following MHRA approval on 11 June. Boots opened its service on 7 July with an introductory price of £79 for new customers on the starter 1.5mg dose, rising to £99 for existing customers, and extended the pill to in-store weight loss services across 62 branches from 12 July. The pharmacy chain said thousands of people completed consultations ahead of launch.
It is the same active ingredient as the Wegovy injection, taken daily on an empty stomach rather than weekly by pen. Dosing starts at 1.5mg and steps up over at least four months to 4mg, 9mg and finally 25mg, mirroring the injectable's titration schedule.
Other providers have followed with their own pricing. Numan charges £129 a month for the starter dose rising to £249 at the top 25mg dose. Chemist4U prices the range from £99 (1.5mg and 4mg) up to £199 at 25mg. Medino undercuts most rivals at £98.99 to £179.99 across the four doses. Superdrug has confirmed it will offer the pill but had not published pricing at the time of writing.
| Provider | Starter 1.5mg | Top dose 25mg |
|---|---|---|
| Boots Online Doctor | £79 new-customer offer | Not yet published |
| Medino | £98.99 | £179.99 |
| Chemist4U | £99 | £199 |
| Numan | £129 | £249 |
If you would rather take a tablet than inject, you now have a genuine choice, but prices vary by more than £100 a month for the same medicine at the same dose, and several providers, including Superdrug, have not published prices yet. Do not commit to the first offer you see: compare like-for-like doses across providers, and factor in whether introductory pricing jumps after your first month.
NICE begins its review of orforglipron, Eli Lilly's rival weight-loss pill
While oral Wegovy is only available privately for now, NICE has started the process that could eventually bring a second weight-loss pill, orforglipron, onto the NHS. A NICE committee met on 14 July 2026 to begin assessing the drug's clinical and cost effectiveness for managing obesity or overweight with a related health condition, with published guidance expected around 18 November 2026.
Orforglipron is not yet licensed for use in the UK. The NICE appraisal is running in parallel with the regulatory process rather than waiting for it, but a positive recommendation is not guaranteed, and any NHS rollout would follow several months after guidance is published.
Nothing changes for NHS access yet. This is the start of a review, not a decision. If you are hoping for NHS-funded access to an oral GLP-1, the realistic timeline is into 2027 at the earliest. In the meantime, oral Wegovy remains a private-only option, priced as above.
Just how many people in the UK are now on a GLP-1?
New figures put a number on how mainstream weight-loss drugs have become. More than 4 million items of semaglutide and tirzepatide were dispensed on the NHS in England in 2025/26, while roughly 2.5 million people a month were accessing GLP-1s privately by the end of 2025. Analysts now expect around 3.3 million UK adults to use weight-loss injections at some point in 2026.
The private market has grown largely because NHS access remains tightly restricted by BMI and comorbidity criteria, and because supply constraints pushed many patients towards paid-for routes when the drugs first launched.
You are far from alone if you are paying privately: most current GLP-1 users in the UK are doing exactly that. It also means demand is not slowing down, so expect continued competition on price between providers, which is useful if you compare options rather than staying with the first one you tried.
Beyond weight loss: hair loss, ED, TRT and blood testing
- Cocoon has rolled its at-home phlebotomy service out UK-wide, sending clinicians to people's homes for full venous blood draws, the same sample type hospitals use rather than a finger-prick kit, with digital results back in 48 to 72 hours plus GP-led review.
- NHS England has opened early market engagement with private providers for blood self-sampling services, as part of building a private beta for a digital NHS Health Check, a signal the health service is looking at the same at-home testing model.
- Leger Clinic is running a TRT consultation offer at £149, down from £258, as competition in the private testosterone replacement market continues to build.
- The Online GP is offering ED consultations from £59 and a broader men's health package at £495, covering hormone and cardiovascular blood panels alongside a 12-week review.
- Hair loss research moved forward this month too: enrolment has completed across all-male Phase 3 trials of VDPHL01 for pattern hair loss, and a trial of Cinainu, a topical botanical treatment, published positive regrowth results in children and adolescents with alopecia areata in the British Journal of Dermatology.
Market and investment
- Semble, the outpatient practice management platform used by many UK private clinics, raised a €34.7m, about $40.4m, Series C to expand its EHR, scheduling and payments platform across the UK and Europe.
- 01Health closed a Series A round to build infrastructure that lets local clinics deliver specialist services, with plans to roll out across the UK before expanding into the US.
- UK and European digital health funding hit $7.4bn in the year to date, according to Rock Health, with clinical workflow software the single biggest category by both deal count and capital raised.
- Medneo struck a six-year deal with Ramsay Health Care UK, acquiring Ramsay Diagnostics UK's mobile MRI and CT fleet and taking on mobile imaging services across Ramsay's hospital network.
Women's health
- The Women's Digital Health Challenge has expanded from 2 to 26 supported innovations, including Gracefully, MenoSaathi and Jalititi.
- England's renewed Women's Health Strategy, published in April, continues to shape how women's health hubs are rolled out, aiming to bring multiple services into a single appointment rather than several separate referrals.
- At HETT North in Manchester, speakers pointed to electronic patient records and self-referral tools as the biggest near-term change in maternity and women's health services, while also warning that digital exclusion risks leaving some women behind if access to smartphones or the internet is patchy.
Medical disclaimer
This article is for general information only and is not medical advice. GLP-1 medicines are prescription-only treatments. Always speak to a qualified healthcare professional before making decisions about weight-loss medication, changing treatment, or choosing a provider.
Sources
- Boots Online Doctor launches new oral Wegovy weight loss pill, Boots UK Newsroom
- Boots launches new oral Wegovy weight loss pill from £79 as thousands sign up, Yahoo News UK
- First GLP-1 tablet for weight loss approved in the UK, GOV.UK / MHRA
- Oral Wegovy Price Comparison UK 2026, Simple Online Pharmacy
- Wegovy Pill Price Comparison UK, Medino
- Orforglipron for managing overweight and obesity [ID6516], NICE
- Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK, News-Medical
- Cocoon Brings Hospital-Grade Blood Testing into UK Homes, News Anyway
- NHS launches pre-market engagement for at-home blood tests, Pathology in Practice
- Leger Clinic, TRT pricing and clinical articles
- Erectile Dysfunction Treatment London 2026, The Online GP
- Digital Health Coffee Time Briefing, Digital Health
- Women's health programme expands from 2 to 26 innovations, Digital Health
- Digital health VC funding hits $7.4B so far in 2026, Modern Healthcare / Rock Health
